Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 13/20 | 0.55 |
| ▸ | BACE1 | P56817 | 5/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.46 |
| ▸ | CHRNG | P07510 | 2/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.46 |
| ▸ | CHRND | Q07001 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622334 | 1.00 | REN (0.55) | RENBACE1CTSDBACE2CHRNA1 | |
| SCHEMBL4038384 | 0.96 | REN (0.62) | REN | |
| SCHEMBL4622204 | 0.95 | BACE1 (0.50) | RENBACE1CTSDBACE2 | |
| SCHEMBL4622201 | 0.95 | BACE1 (0.50) | RENBACE1CTSDBACE2 | |
| SCHEMBL4044533 | 0.88 | REN (0.60) | RENBACE1CTSDBACE2 | |
| SCHEMBL4044535 | 0.88 | REN (0.60) | RENBACE1CTSDBACE2 | |
| SCHEMBL4623288 | 0.85 | REN (0.51) | RENBACE1CTSDBACE2 | |
| SCHEMBL4622315 | 0.85 | REN (0.51) | RENBACE1CTSDBACE2 | |
| SCHEMBL4622308 | 0.85 | REN (0.51) | RENBACE1CTSDBACE2 | |
| SCHEMBL4622135 | 0.84 | REN (0.55) | RENBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| US-20080070885-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2008-03-20 | — | — | US | disclosed |
| EP-1654241-B1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-20060223745-A1 | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof | BETSCHART CLAUDIA | 2006-10-05 | — | — | US | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223745-A1 | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof | BACE1, APP, ACE | REN 54/4885BACE1 1/4885CTSD 103/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | REN 116/4885BACE1 1/4885CTSD 14/4885 |
| US-20080070885-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | BACE1, APP, BACE2 | REN 68/4885BACE1 1/4885CTSD 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.